Clinical Trial Update: Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adding oxaliplatin and capecitabine to sorafenib versus sorafenib alone for advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Sanofi | Conditions: Hepatic Neoplasm Malignant | Phase 3 | Status: WITHDRAWN